Cargando…

Potential prophylactic efficacy of mast cell stabilizers against COVID-19 vaccine-induced anaphylaxis

To fight against coronavirus disease 2019 (COVID-19), the vaccination is currently the most effective approach. However, in addition to common systemic side effects, the vaccines can cause serious allergic reactions or anaphylaxis. In anaphylaxis, the exposure to the allergen causes a sudden release...

Descripción completa

Detalles Bibliográficos
Autor principal: Kazama, Itsuro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666472/
https://www.ncbi.nlm.nih.gov/pubmed/34903238
http://dx.doi.org/10.1186/s12948-021-00162-9
_version_ 1784614213067472896
author Kazama, Itsuro
author_facet Kazama, Itsuro
author_sort Kazama, Itsuro
collection PubMed
description To fight against coronavirus disease 2019 (COVID-19), the vaccination is currently the most effective approach. However, in addition to common systemic side effects, the vaccines can cause serious allergic reactions or anaphylaxis. In anaphylaxis, the exposure to the allergen causes a sudden release of chemical mediators from mast cells, for which adrenaline is the drug of first choice. In our previous basic studies, in addition to adrenaline, anti-allergic drugs (olopatadine, loratadine, tranilast and ketotifen), antibiotics (clarithromycin), corticosteroids (hydrocortisone and dexamethasone) and certain food constituents (caffeine and catechin) inhibited the process of exocytosis and showed their effectiveness as highly potent mast cell stabilizers. In these studies, since mast cells were pre-incubated with these drugs or the food constituents before exocytosis was induced, the findings strongly indicated their prophylactic efficacy in stabilizing mast cells. Considering such pharmacological properties of these commonly prescribed medications or the food constituents, their prophylactic use may potentially be beneficial in preventing anaphylaxis caused by COVID-19 vaccination.
format Online
Article
Text
id pubmed-8666472
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-86664722021-12-13 Potential prophylactic efficacy of mast cell stabilizers against COVID-19 vaccine-induced anaphylaxis Kazama, Itsuro Clin Mol Allergy Letters to the Editor To fight against coronavirus disease 2019 (COVID-19), the vaccination is currently the most effective approach. However, in addition to common systemic side effects, the vaccines can cause serious allergic reactions or anaphylaxis. In anaphylaxis, the exposure to the allergen causes a sudden release of chemical mediators from mast cells, for which adrenaline is the drug of first choice. In our previous basic studies, in addition to adrenaline, anti-allergic drugs (olopatadine, loratadine, tranilast and ketotifen), antibiotics (clarithromycin), corticosteroids (hydrocortisone and dexamethasone) and certain food constituents (caffeine and catechin) inhibited the process of exocytosis and showed their effectiveness as highly potent mast cell stabilizers. In these studies, since mast cells were pre-incubated with these drugs or the food constituents before exocytosis was induced, the findings strongly indicated their prophylactic efficacy in stabilizing mast cells. Considering such pharmacological properties of these commonly prescribed medications or the food constituents, their prophylactic use may potentially be beneficial in preventing anaphylaxis caused by COVID-19 vaccination. BioMed Central 2021-12-13 /pmc/articles/PMC8666472/ /pubmed/34903238 http://dx.doi.org/10.1186/s12948-021-00162-9 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Letters to the Editor
Kazama, Itsuro
Potential prophylactic efficacy of mast cell stabilizers against COVID-19 vaccine-induced anaphylaxis
title Potential prophylactic efficacy of mast cell stabilizers against COVID-19 vaccine-induced anaphylaxis
title_full Potential prophylactic efficacy of mast cell stabilizers against COVID-19 vaccine-induced anaphylaxis
title_fullStr Potential prophylactic efficacy of mast cell stabilizers against COVID-19 vaccine-induced anaphylaxis
title_full_unstemmed Potential prophylactic efficacy of mast cell stabilizers against COVID-19 vaccine-induced anaphylaxis
title_short Potential prophylactic efficacy of mast cell stabilizers against COVID-19 vaccine-induced anaphylaxis
title_sort potential prophylactic efficacy of mast cell stabilizers against covid-19 vaccine-induced anaphylaxis
topic Letters to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666472/
https://www.ncbi.nlm.nih.gov/pubmed/34903238
http://dx.doi.org/10.1186/s12948-021-00162-9
work_keys_str_mv AT kazamaitsuro potentialprophylacticefficacyofmastcellstabilizersagainstcovid19vaccineinducedanaphylaxis